Diabetes Technology Society, Burlingame, CA, USA.
Medtronic Diabetes, Northridge, CA, USA.
J Diabetes Sci Technol. 2021 May;15(3):705-709. doi: 10.1177/1932296821999080. Epub 2021 Mar 11.
Continuous subcutaneous insulin infusion (CSII) is becoming increasingly used for achieving target glycemic control as well as providing flexibility in lifestyle. In a widely used version of CSII, the insulin pump itself is attached to one end of an insulin infusion set (IIS), which delivers insulin via a thin flexible plastic tube to the patient's body via a cannula or needle that is inserted under the skin at the other end of the IIS. Despite the increased use of CSII by patients with diabetes, there have been few recent advances in IIS technology, especially when compared to the many recent advances made in insulin pump technology and in insulin pharmacokinetics. To discuss recent developments in, and future plans for IIS development, Diabetes Technology Society virtually hosted the Advances in Insulin Pump Infusion Sets Symposium on December 1, 2020. This symposium featured experts in the field of IISs, including representatives from Medtronic and ConvaTec (which are two manufacturers that are currently developing IISs), Stanford University, Steno Diabetes Center Copenhagen, and Science Consulting in Diabetes. The webinar's six speakers covered (1) patient burden, (2) extended wear technology, and (3) future directions in IIS development.
持续皮下胰岛素输注 (CSII) 正越来越多地被用于实现目标血糖控制，同时为生活方式提供灵活性。在 CSII 的一种广泛使用的版本中，胰岛素泵本身连接到胰岛素输注套件 (IIS) 的一端，该套件通过一根薄而灵活的塑料管将胰岛素输送到患者体内，通过在 IIS 另一端插入皮下的套管或针头。尽管糖尿病患者越来越多地使用 CSII，但 IIS 技术几乎没有取得什么新进展，尤其是与胰岛素泵技术和胰岛素药代动力学方面的许多最新进展相比。为了讨论 IIS 开发的最新进展和未来计划，糖尿病技术协会于 2020 年 12 月 1 日虚拟举办了胰岛素泵输注套件进展研讨会。该研讨会的特色是 IIS 领域的专家，包括美敦力和康维特（这两家目前正在开发 IIS 的制造商）、斯坦福大学、哥本哈根 Steno 糖尿病中心和糖尿病科学咨询公司的代表。网络研讨会的六位演讲者涵盖了（1）患者负担、（2）延长佩戴技术以及（3）IIS 开发的未来方向。
